HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme

By Raizer Jeffrey  

Journal of Neuro-Oncology, Vol. 74, Iss. 1, 2005-08 ,pp. : 77-86

Springer Publishing Company

Access to resources Recommend Favorite

Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung

By Lee Youngjoo   Han Ji-Youn   Kim Heung   Yun Tak   Lee Geon   Kim Hyae   Lee Jin  

Journal of Neuro-Oncology, Vol. 115, Iss. 1, 2013-10 ,pp. : 95-101

Springer Publishing Company

Access to resources Recommend Favorite

Clinical development of EGFR-tyrosine kinase inhibitors in Japan

By Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 1, 2006-11 ,pp. : 33-37

Springer Publishing Company

Access to resources Recommend Favorite

Clinical development of EGFR-tyrosine kinase inhibitors in Japan

By Nakagawa Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 7, 2006-11 ,pp. : 33-37

Springer Publishing Company

Access to resources Recommend Favorite

Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models

By Chen Jianping   Smith Melissa   Kolinsky Kenneth   Adames Violeta   Mehta Nila   Fritzky Luke   Rashed Mohammad   Wheeldon Eric   Linn Michael   Higgins Brian  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 651-659

Springer Publishing Company

Access to resources Recommend Favorite